Lessons learned from Zaire ebolavirus to help address urgent needs for vaccines against Sudan ebolavirus and Marburg virus

References

• Agency EM Ervebo; 2019 Dec 17 [accessed 2019 Dec 20]. https://www.ema.europa.eu/en/medicines/human/EPAR/ervebo.
   Google Scholar
• Administration FD First FDA-approved vaccine for the prevention of Ebola virus disease, marking a critical milestone in public health preparedness and response. 2019 [ accessed 2019 Dec 17]. https://www.fda.gov/news-events/press-announcements/first-fda-approved-vaccine-prevention-ebola-virus-disease-marking-critical-milestone-public-health
   Google Scholar
• Wolfe DN, Zarrabian AG, Disbrow GL, Espeland EM. Progress towards a vaccine against Ebola to meet emergency medical countermeasure needs. Vaccine. 2017;17:7178–82.
   Google Scholar
• Heymann D, Hodgson A, Sall AA, Freedman DO, Staples JE, Althabe F, Baruah K, Mahmud G, Kandun N, Vasconcelos PFC, et al. Zika virus and microencephaly: why is this situation a PHEIC. Lancet. 2016;387(10020):719–21. doi:10.1016/S0140-6736(16)00320-2.
   PubMed Web of Science ®Google Scholar
• Taubengerger J, Morens DM. Pandemic influenza - including a risk assessment of H5N1. Rev Sci Technol. 2009;28(1):187–202. doi:10.20506/rst.28.1.1879.
   PubMed Web of Science ®Google Scholar
• Silva W, Das TK, Izurieta R. Estimating disease burden of a potential A (H7N9) pandemic influenza outbreak in the United States. BMC Public Health. 2017;17(1):898. doi:10.1186/s12889-017-4884-5.
   PubMedGoogle Scholar
• Prevention, C.f.D.C.a. Outbreaks chronology: Ebola virus diseae. 2016 [accessed 2017 Jul 1]. http://www.cdc.gov/vhf/ebola/outbreaks/history/chronology.html
   Google Scholar
• Prevention, C.f.D.C.a. Chronology of Marburg hemorrhagic fever outbreaks. 2014 [accessed 2017 Jul 1] https://www.cdc.gov/vhf/marburg/resources/outbreak-table.html
   Google Scholar
• Goldstein T, Anthony SJ, Gbakima A, Bird BH, Bangura J, Tremeau-Bravard A, Belaganahalli MN, Wells HL, Dhanota JK, Liang E, et al. The discovery of Bombali virus adds further support for bats as hosts of ebolaviruses. Nat Microbiol. 2018;3(10):1084–89. doi:10.1038/s41564-018-0227-2.
   PubMed Web of Science ®Google Scholar
• Wasswa H. Uganda grapples wiht new Marburg disease outbreak. BMJ. 2017;359:5252. doi:10.1136/bmj.j5252.
   Google Scholar
• Ledgerwood J, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29(2):304–13. doi:10.1016/j.vaccine.2010.10.037.
   PubMed Web of Science ®Google Scholar
• Martin J, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomez PL, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase 1 clinical trial. Clin Vaccine Immunol. 2006;13(11):1267–77. doi:10.1128/CVI.00162-06.
   PubMed Web of Science ®Google Scholar
• Herbert A, Kuehne AI, Barth JF, Ortiz RA, Nichols DK, Zak SE, Stonier SW, Muhammad MA, Bakken RR, Prugar LI, et al. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus. J Virol. 2013;87(9):4952–64. doi:10.1128/JVI.03361-12.
   PubMed Web of Science ®Google Scholar
• Martins KAO, Cooper CL, Stronsky SM, Norris SLW, Kwilas SA, Steffens JT, Benko JG, van Tongeren SA, Bavari S. Adjuvant-enhanced CD4 T cell responses are critical to durable vaccine immunity. EBioMedicine. 2015;27(3):67–78.
   Google Scholar
• Geisbert T, Feldmann H. Recombinant vesicular stomatitis virus–based vaccines against Ebola and Marburg virus infections. J Infect Dis. 2011;204(Supplement 3):S1075–1081. doi:10.1093/infdis/jir349.
   PubMedGoogle Scholar
• Stanley DA, Honko A, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20(10):1126–29. doi:10.1038/nm.3702.
   PubMed Web of Science ®Google Scholar
• Geisbert T, Bailey M, Hensley L, Asiedu C, Geisbert J, Stanley D, Honko A, Johnson J, Mulangu S, Pau MG, et al. Recombinant adenovirus serotype 26 (Ad26) and Ad35 vaccine vectors bypass immunity to Ad5 and protect nonhuman primates against ebolavirus challenge. J Virol. 2011;85(9):4222–33. doi:10.1128/JVI.02407-10.
   PubMed Web of Science ®Google Scholar
• Cross R, Mire CE, Feldmann H, Geisbert TW. Post-exposure treatments for Ebola and Marburg virus infections. Nat Rev Drug Discov. 2018;22(218):S448–S452.
   Web of Science ®Google Scholar
• Administration, F.a.D. Product development under the animal rule. Guidance for Industry. C.f.D.E.a.R.C.f.B.E.a. Research, Editor. 2015 [accessed 2019 Dec 12]. https://www.fda.gov/downloads/drugs/guidances/ucm399217.pdf
   Google Scholar
• Alfson K, Avena LE, Beadles MW, Staples H, Nunneley JW, Ticer A, Dick EJ, Owston MA, Reed C, Patterson JL, et al. Particle-to-PFU ratio of Ebola virus influences disease course and survival in cynomolgus macaques. J Virol. 2015;89(13):6773–81. doi:10.1128/JVI.00649-15.
   PubMed Web of Science ®Google Scholar
• Geisbert T, Strong JE, Feldmann H. Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. J Infect Dis. 2015;212(Supplement 2):S91–97. doi:10.1093/infdis/jiv284.
   PubMedGoogle Scholar
• Marzi A, Feldmann H. Ebola virus vaccines: an overview of current approaches. Expert Rev Vaccines. 2014;13(4):521–31. doi:10.1586/14760584.2014.885841.
   PubMed Web of Science ®Google Scholar
• Mire CE, Miller AD, Carville A, Westmoreland SV, Geisbert JB, Mansfield KG, Feldmann H, Hensley LE, Geisbert TW. Recombinant vesicular stomatitis virus vaccine vectors expressing filovirus glycoproteins lack neurovirulence in nonhuman primates. PLoS Negl Trop Dis. 2012;6(3):1567. doi:10.1371/journal.pntd.0001567.
   PubMed Web of Science ®Google Scholar
• Jones SM, Stroher U, Fernando L, Qiu X, Alimonti J, Melito P, Bray M, Klenk HD, Feldmann H. Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever. J Infect Dis. 2007;196:S404–S412. doi:10.1086/525008.
   PubMed Web of Science ®Google Scholar
• Al-Humadi N. Pre-clinical toxicology consideratinos for vaccine development. Vaccine. 2017;35(43):5762–67. doi:10.1016/j.vaccine.2017.09.021.
   PubMed Web of Science ®Google Scholar
• Sullivan N, Martin J, Graham B, Nabel G. Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule. Nat Rev Microbiol. 2009;7(4):393–400. doi:10.1038/nrmicro2129.
   PubMedGoogle Scholar
• Rudge TL Jr, Sankovich KA, Niemuth NA, Anderson MS, Badorrek CS, Skomrock ND, Cirimotich CM, Sabourin CL. Development, qualification, and validation of the filovirus animal nonclinical group anti-Ebola virus glycoprotein immunoglobulin G enzyme-linked immunosorbent assay for human serum samples. PLoS One. 2019;14(4):e0215457. doi:10.1371/journal.pone.0215457.
   PubMed Web of Science ®Google Scholar
• Kibuuka H, Berkowitz N, Millard M, Enama ME, Tindikahwa A, Sekiziyivu AB, Costner P, Sitar S, Glover D, Hu Z, et al. Safety and immunogenicity of Ebola virus and Marburg virus glycoprotein DNA vaccines assessed separately and concomitantly in healthy Ugandan adults: a phase 1b, randomised, double-blind, placebo-controlled clinical trial. Lancet. 2015;385(9977):1545–54. doi:10.1016/S0140-6736(14)62385-0.
   PubMed Web of Science ®Google Scholar
• Reynolds P, Marzi A. Ebola and Marburg virus vaccines. Virus Genes. 2017;53(4):501–15. doi:10.1007/s11262-017-1455-x.
   PubMed Web of Science ®Google Scholar
• Suschak J, Schmaljohn CS. Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates. Hum Vaccines Immunotherapeutics. 2019;15(10):2359–77. doi:10.1080/21645515.2019.1651140.
   PubMed Web of Science ®Google Scholar
• Hirschberg R, Ward LA, Kilgore N, Kurnat R, Schiltz H, Albrecht MT, Christopher GW, Nuzum E. Challenges, progress, and opportunities: proceedings of the Filovirus medical countermeasures workshop. Viruses. 2014;6(7):2673–97. doi:10.3390/v6072673.
   PubMed Web of Science ®Google Scholar
• Smither SJ, Nelson M, Eastaugh L, Nunez A, Salguero FJ, Lever MS. Experimental respiratory infection of marmosets (Callithrix jacchus) with Ebola virus kikwit. J Infect Dis. 2015;212(Suppl 2):S336–345. doi:10.1093/infdis/jiv371.
   PubMedGoogle Scholar
• Kroeker A, He S, de La Vega M, Wong G, Embury-Hyatt C, Qiu X. Characterization of Sudan Ebolavirus infection in ferrets. Oncotarget. 2017;8(28):46262–72. doi:10.18632/oncotarget.17694.
   PubMedGoogle Scholar
• Cross RW, Mire CE, Borsevich V, Geisbert JB, Fenton KA, Geisbert TW. The domestic ferret (Mustela putorius furo) as a lethal infection model for 3 species of ebolavirus. J Infect Dis. 2016;214(4):565–69. doi:10.1093/infdis/jiw209.
   PubMed Web of Science ®Google Scholar
• Alfson K, Avena LE, Worwa G, Carrion R, Griffiths A. Development of a lethal intranasal exposure model of Ebola virus in the cynomolgus macaque. Viruses. 2017;9(11):319. doi:10.3390/v9110319.
   PubMed Web of Science ®Google Scholar
• Organization WH, Ebola Virus Disease; Democratic Republic of the Congo External Situation Report 71. 2019: https://www.who.int/emergencies/diseases/ebola/drc-2019/situation-reports.
   Google Scholar
• Alliance GTV Gavi Board approves new Ebola vaccine programme. 2019 [ accessed 2019 Dec 6]. https://www.gavi.org/news/media-room/gavi-board-approves-new-ebola-vaccine-programme
   Google Scholar